

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, September 15, 2022

1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/94900334935 Webinar ID: 949 0033 4935 Password: 563831	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 949 0033 4935 Passcode: 563831

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of May 2022 Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Quviviq™ (Sedative Hypnotic Agents)
 - ii. Igalmi™ (Sedative Hypnotic Agents)
 - iii. Ibsrela® (GI Motility Agents)
 - iv. Mounjaro™ (GLP-1 Receptor Agonists)
 - v. Vtama® (Topical Psoriasis Agents)
 - vi. Voquezna™ (H. Pylori Treatment)
 - vii. Camzyos™ (Non-PDL Medication)
- I. Therapeutic Classes with Recommended Changes**
 - a. Ace Inhibitors
 - b. Anticonvulsants: Second Generation
 - c. Antidepressants: Tricyclics
 - d. Dopamine Receptor Agonists
 - e. Antipsychotics: Injectable
 - f. Beta-Blockers
 - g. Calcium Channel Blockers (Non-DHP)
 - h. Movement Disorders
 - i. Pulmonary Arterial Hypertension (PAH) Agents
- II. Consent Agenda**
 - b. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Alzheimer's Agents • Angiotensin Modulators (Angiotensin Receptor Blockers) • Angiotensin Modulator Combinations • Antianginal & Anti-Ischemic • Antiarrhythmics, Oral • Anticoagulants • Anticonvulsants: Carbamazepine Derivatives • Anticonvulsants: First Generation • Antidepressants, Other • Antidepressants, SNRI • Antidepressants, SSRI 	<ul style="list-style-type: none"> • Antiparkinson's Agents (Parkinson's Disease) • Antipsychotics: First-Generation (oral) • Antipsychotics: Second-Generation (oral) • Anxiolytics • Bladder Relaxant Preparations • BPH Treatments • Calcium Channel Blockers (DHP) • Lipotropics, Other • Lipotropics, Statins • Platelet Aggregation Inhibitors • Stimulants and Related Agents • Tobacco Cessation Products/Smoking Cessation
---	---

V. Adjournment

a. Schedule of Upcoming Meetings

i. **November 17, 2022**

ii. **January 19, 2023**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.